Close Navigation
Learn more about IBKR accounts

A Conversation with Jamie Metzl on the BioRevolution

Posted May 12, 2023
Christopher Gannatti
WisdomTree U.S.

Recently, we had the pleasure of speaking with Jamie Metzl, Founder and Chair of One Shared World, and author of the book, Hacking Darwin, which illustrates many of the advances in our ability to use the information encoded in DNA.

The topic: how the coming decades could very well be determined by the unique array of advancements we are on the precipice of making within the space we call the ‘BioRevolution.’ We think this could be one of the defining megatrends of the coming decades, in that, as people think about health and sustainability, advances in certain critical areas will be essential.

Jamie noted that he has been on the leading edge in certain areas under discussion, particularly as a member of the World Health Organization’s expert advisory committee on human genome editing. This committee was created after the birth in China of the first human babies with genes edited via CRISPR technology, to figure out how these very powerful tools can be best deployed for the greatest good.

Roughly 20 years ago, we were seeing the results of the Human Genome Project, and it is a process that has only improved and become more efficient as the years have gone by. Additionally, we note there is intersectionality between the advancements in generative artificial intelligence (AI) (systems like ChatGPT and Progen) and the possibilities available in engineered biology. In fact, Jamie is working on a new book, to be published next year, called The Great Biohack: Recasting Life in an Age of Revolutionary Technology.

Human History Is a Series of Inflection Points

Progress tends not to occur in a smooth line, with regular advances per unit of time, but rather in big step changes. One of those changes was agriculture, when instead of existence relying on finding enough food, food supplies were secured. This meant labor could be divided, such that a part of the population could tend to the farms and another part could focus elsewhere. Another of those changes was industrialization…another was the internet.

In each case, the ways in which humans spend their time as well as what type of outputs they could produce with that time has changed. In 2023, we are seeing advances in:

•  Artificial intelligence

•  Genetics

•  Biotechnology

•  Nanotechnology

And that only names a few. Sometimes people see these as separate, but we can also think of them as parts of the same, bigger technological advance. If we are trying, for instance, to cure a disease, now there could be more tools. If we are trying to have more and better food, now there could be more tools. It’s all about getting more and more tools over time that can be used to help solve these very important issues.

Generative AI Moment

Generative AI systems are designed to look at massive fields of data and come up with statistical predictions about what follows. When this is applied to the internet and written language it creates the experience that many have had with ChatGPT.

But, biology is also its own language, to the extent we all know in spoken or written language the range of things that ‘make sense’ and the range of things that ‘appear incorrect.’ We are learning more about the languages of:

•  Biology

•  Genetics

•  Chemistry

•  Proteins

If the current large language models can train on the language of these specific disciplines, it is possible they could already suggest potentially interesting outputs, be it new molecules, interesting proteins or even possible drug therapies.

Proteins are a particularly interesting area. It’s not only about knowing the amino acids and the sequence or the order—it is also about knowing the structure, because there is a close relationship between structure and function. In 2022, DeepMind released predictions for the structure of more than 200 million proteins—a number that is growing all the time. Meta was able to release structure predictions for something close to 600 million proteins.

AI is not—yet—creating novel drugs in the market, fully approved, from end to end. However, the overall drug development process could be done in less time (the average is around 10 years), for less money (average: $2 billion) and with a lower failure rate (average: 96% failure), so this potential could be quite impactful. 

Conclusion: So Much Will Change in the Coming Decades…

At WisdomTree, when we think of the BioRevolution, we think of four areas:

1.  Human health

2.  Agriculture and food

3.  Materials, chemicals and energy

4.  Biological machines and interfaces

There is simply too much happening in each of these areas to cover in a short written piece, but we note two things for anyone looking to delve a bit further:

1.  The full video and transcript of the conversation we had with Jamie Metzl is available here.

2.  Further information on the WisdomTree BioRevolution Fund (WDNA) is available here.

Originally Posted May 11, 2023 – A Conversation with Jamie Metzl on the BioRevolution

Join The Conversation

If you have a general question, it may already be covered in our FAQs. If you have an account-specific question or concern, please reach out to Client Services.

Leave a Reply

Your email address will not be published. Required fields are marked *

Disclosure: WisdomTree U.S.

Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds before investing. U.S. investors only: To obtain a prospectus containing this and other important information, please call 866.909.WISE (9473) or click here to view or download a prospectus online. Read the prospectus carefully before you invest. There are risks involved with investing, including the possible loss of principal. Past performance does not guarantee future results.

You cannot invest directly in an index.

Foreign investing involves currency, political and economic risk. Funds focusing on a single country, sector and/or funds that emphasize investments in smaller companies may experience greater price volatility. Investments in emerging markets, real estate, currency, fixed income and alternative investments include additional risks. Due to the investment strategy of certain Funds, they may make higher capital gain distributions than other ETFs. Please see prospectus for discussion of risks.

WisdomTree Funds are distributed by Foreside Fund Services, LLC, in the U.S. only.

Interactive Advisors offers two portfolios powered by WisdomTree: the WisdomTree Aggressive and WisdomTree Moderately Aggressive with Alts portfolios.

Disclosure: Interactive Brokers

Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from WisdomTree U.S. and is being posted with its permission. The views expressed in this material are solely those of the author and/or WisdomTree U.S. and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

IBKR Campus Newsletters

This website uses cookies to collect usage information in order to offer a better browsing experience. By browsing this site or by clicking on the "ACCEPT COOKIES" button you accept our Cookie Policy.